ÖZET
Amaç:
Kromozomal anormallikler, akut miyeloid lösemide (AML) en önemli prognostik faktörlerden biridir. Bununla birlikte, tüm hastalarda bu tür bilgilendirici kromozomal anormallikler olmayabilir. AML’de immünofenotiplemenin prognostik değeri üzerine birçok çalışma olmasına rağmen, immünofenotipleme halen prognostik belirteç olarak kullanılmamaktadır. Bu çalışmada akut promiyelositik lösemi dışı AML’de CD13, CD33, CD34, CD117, MPO ve HLADR ekspresyonlarının prognoz üzerindeki etkilerini araştırmayı amaçladık.
Yöntemler:
Bu çalışmaya 2010-2018 yılları arasında tanı konup tedavi edilen 113 akut promiyelositik lösemi dışı AML’li hasta dahil edilmiştir. CD13, CD33, CD34, CD117, MPO ve HLA DR ekspresyonlarının kemoterapi yanıtı ve progresyonsuz (PFS) ve genel sağkalım (OS) ile ilişkisi istatistiksel olarak analiz edildi.
Bulgular:
Hastaların %67,3’ünde kemoterapiye yanıt alındığı görüldü. Medyan PFS süresi 9 aydı ve medyan OS süresi 13 ay olarak bulundu. İmmünofenotipik özelliklerden yalnızca MPO ekspresyonunun, PFS ve OS için bağımsız bir risk faktörü olduğu belirlendi.
Sonuç:
İmmünofenotipik özellikler AML tanısında yardımcı olabileceği gibi prognoz hakkında da fikir verebilir. Bu çalışmada, MPO ekspresyonunun kendi hasta popülasyonumuzda PFS ve OS için bağımsız bir risk faktörü olduğu gösterilmiştir.
References
1
https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html.
2
Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 2004; 103:4036-42.
3
Olesen LH, Aggerholm A, Andersen BL, Nyvold CG, Guldberg P, Norgaard JM, et al. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol 2005;131:457-67.
4
Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer 2001;92:1059-73.
5
Timilshina N, Breunis H, Brandwein JM, Minden MD, Gupta V, O’Neill S, et al. Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML? Ann Oncol 2014;25:883-8.
6
Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015;125:1367-76.
7
Creutzig U, Buchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008;112:562-71.
8
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-47.
9
Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev 2006;20:71-82.
10
San Miguel JF, Ojeda E, Gonzalez M, Orfao A, Canizo MC, Sanchez J, et al. Prognostic value of immunological markers in acute myeloblastic leukemia. Leukemia 1989;3:108-11.
11
Tucker J, Dorey E, Gregory WM, Simpson AP, Amess JA, Lister TA, et al. Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol 1990;8:47-58.
12
Solary E, Casasnovas RO, Campos L, Bene MC, Faure G, Maingon P, et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d’Etude Immunologique des Leucemies (GEIL). Leukemia 1992;6:393-9.
13
Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989;72:161-6.
14
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011;117:2358-65.
15
Matsuo T, Kuriyama K, Miyazaki Y, Yoshida S, Tomonaga M, Emi N, et al. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia 2003;17:1538-43.
16
Taguchi J, Miyazaki Y, Tsutsumi C, Sawayama Y, Ando K, Tsushima H, et al. Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia. Leuk Res 2006;30:1105-12.
17
Sawayama Y, Miyazaki Y, Ando K, Horio K, Tsutsumi C, Imanishi D, et al. Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of protein. Leukemia 2008;22:956-64.
18
Dong XY, Li YL, Jiang L, Wu CY, Shang BJ, Zhang L, et al. [Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019;40:40-5.
19
Kamijo R, Itonaga H, Kihara R, Nagata Y, Hata T, Asou N, et al. Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. Leuk Res 2018;65:34-41.
20
Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004;28:43-8.
21
Myint H, Lucie NP. The prognostic significance of the CD34 antigen in acute myeloid leukaemia. Leuk Lymphoma 1992;7:425-9.
22
Raspadori D, Lauria F, Ventura MA, Rondelli D, Visani G, de Vivo A, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 1997; 21:603-7.
23
Yang LL, Liu X, Li Q, Zhu XY, Wang XB, Zhu WB. [Immunophenotyping characteristics of AML and their correlation with the curative effects]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2014;22:1-5.
24
Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 2003;53:11-9.
25
Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000;96:870-7.
26
Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer 2008;112:572-80.
27
Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, et al. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986;68:1232-41.
28
Schwarzinger I, Valent P, Köller U, Marosi C, Schneider B, Haas O, et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990;8:423-30.
29
Ashman LK, Roberts MM, Gadd SJ, Cooper SJ, Juttner CA. Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. Leuk Res 1988;12:923-8.
30
Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
31
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9.
32
Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood 2008;111:2527-37.
33
Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61:7233-9.
34
Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, et al. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 2012;118:5819-22.
35
Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
36
Munoz L, Aventin A, Villamor N, Junca J, Acebedo G, Domingo A, et al. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003;88:637-45.
37
Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995;84:60-8.
38
Callea V, Morabito F, Martino B, Stelitano C, Oliva B, Nobile F. Diagnostic and prognostic relevance of the immunophenotype in acute myelocytic leukemia. Tumori 1991;77:28-31.
